LSTA Q3 2023 Earnings — Lisata Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

LSTALisata Therapeutics, Inc.

$44M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$6M

Net Income

-$5M

EPS (Diluted)

$-0.65

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$307,000

Balance Sheet

Total Assets

$58M

Total Liabilities

$5M

Stockholders' Equity

$53M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$6M	-$38M	+84.2%
Net Income	-$5M	-$37M	+85.9%